Article Text

Download PDFPDF
Original research article
Tricuspid regurgitation severity after atrial septal defect closure or pulmonic valve replacement
  1. Agustin C Martin-Garcia1,2,3,
  2. Konstantinos Dimopoulos1,2,
  3. Maria Boutsikou1,2,
  4. Ana Martin-Garcia3,
  5. Aleksander Kempny1,2,
  6. Rafael Alonso-Gonzalez1,2,
  7. Lorna Swan1,2,
  8. Anselm Uebing1,2,
  9. Sonya V Babu-Narayan1,2,
  10. Pedro Luis Sanchez3,
  11. Wei Li1,2,4,
  12. Darryl Shore1,2,
  13. Michael A Gatzoulis1,2
  1. 1Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom
  2. 2National Heart and Lung Institute, Imperial College London, London, UK
  3. 3Cardiology Department, University Hospital of Salamanca Instituto de Investigación Biomédica de Salamanca (IBSAL) Facultad de Medicina Universidad de Salamanca, CIBERCV, Salamanca, Spain
  4. 4Department of Echocardiology, Royal Brompton Hospital, London, UK
  1. Correspondence to Dr Konstantinos Dimopoulos, Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London SW3 6NP, UK; k.dimopoulos02{at}gmail.com

Footnotes

  • ACM-G and KD contributed equally.

  • Contributors All coauthors have agreed to, seen and approved the manuscript for its submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests ACM-G has received support from the Instituto de Investigacion Biomedica de Salamanca (IBSAL). KD, AK and AM-G from the Royal Brompton Hospital have received unrestricted educational and research grants and acted as consultants for Bayer, Pfizer, Actelion and GSK. SVB-N was supported by the British Heart Foundation (FS/11/38/28864).

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

View Full Text

Statistics from Altmetric.com

Footnotes

  • ACM-G and KD contributed equally.

  • Contributors All coauthors have agreed to, seen and approved the manuscript for its submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests ACM-G has received support from the Instituto de Investigacion Biomedica de Salamanca (IBSAL). KD, AK and AM-G from the Royal Brompton Hospital have received unrestricted educational and research grants and acted as consultants for Bayer, Pfizer, Actelion and GSK. SVB-N was supported by the British Heart Foundation (FS/11/38/28864).

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.